CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Total Liabilities
Everything the company owes to creditors and other parties.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 565.6% from a year ago
Total liabilities stood at $74.56M at the end of Q1 FY2026, up 565.6% from a year earlier and up 6.3% from the prior quarter.
Context
- Total liabilities amounted to 70.7% of total assets at the end of Q1 FY2026, up 52.9 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +565.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 70.1M USD
- Year-over-year change
- +362.3%
- 4-year CAGR
- -31.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.1M | +362.3% |
| FY2024 | 2024-12-31 | 15.16M | -91.5% |
| FY2023 | 2023-12-31 | 178.68M | -0.8% |
| FY2022 | 2023-02-28 | 180.08M | -44.1% |
| FY2021 | 2022-02-28 | 322.11M | — |
Total Liabilities vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +565.6% is the highest of 9, against a peer median of -17.7%.
- Total liabilities amounts to 70.7% of total assets for CAMP, versus a peer median of 31.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.94M USD | -23.9% | +31.5% | 47.7% | |
| Mar 2026 | $74.56M USD | +565.6% | — | 70.7% | |
| Mar 2026 | $27.67M USD | +5.1% | +11.8% | 59.6% | |
| Mar 2026 | $26.98M USD | -17.2% | -8.4% | 15.1% | |
| Mar 2026 | $26.7M USD | +60.1% | +79.3% | 41.5% | |
| Mar 2026 | $21.91M USD | -2.1% | +3.1% | 27.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $12.32M USD | -22.8% | +17.0% | 11.4% |
| Mar 2026 | $8.6M USD | -18.2% | -21.3% | 8.9% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$8.19M CAD | -59.9% | +4.3% | 35.4% |
| Peer median (excluding CAMP) | — | -17.7% | +8.0% | 31.4% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 91.11M | 83.19M | 38.38M | 64.04M | 109.52M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 58.59M | 678K | 442K | 108K | 155K |
| Inventory | 20.18M | 0 | 0 | 0 | 0 |
| Other Current Assets | 23.71M | 205K | 245K | 211K | 4.42M |
| Total Current Assets | 193.59M | 84.41M | 40.01M | 66.38M | 114.1M |
| Property, Plant & Equipment (Net) | 50.06M | 16.8M | 13.31M | 10.3M | 2.74M |
| Goodwill | 94M | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.01M | 0 | 0 | 0 | 0 |
| Long-term Investments | 24.34M | 0 | 0 | 0 | 894K |
| Tax Assets | 4.23M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.05M | 1.35M | 1.62M | 1.62M | 83K |
| Total Non-current Assets | 208.7M | 18.14M | 14.93M | 11.92M | 3.71M |
| Total Assets | 402.29M | 102.55M | 54.95M | 78.31M | 117.81M |
| Account Payables | 30.78M | 2.15M | 1.04M | 1.21M | 182K |
| Short-term Debt | 7.74M | 0 | 0 | 0 | 286K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 32.4M | 0 | 0 | 385K | 9.39M |
| Other Current Liabilities | 23.96M | 1.78M | 2.34M | 3.2M | 5.66M |
| Total Current Liabilities | 94.88M | 7.95M | 7.81M | 9.6M | 15.51M |
| Long-term Debt | 201.43M | 0 | 0 | 0 | 1.69M |
| Deferred Tax Liabilities | 208K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.49M | 0 | 0 | 0 | 8.11M |
| Other Non-current Liabilities | 11.1M | 162.11M | 162.23M | 2K | 44.79M |
| Total Non-current Liabilities | 227.23M | 172.13M | 170.87M | 5.57M | 54.59M |
| Total Liabilities | 322.11M | 180.08M | 178.68M | 15.16M | 70.1M |
| Common Stock | 359K | 1K | 1K | 2K | 6K |
| Retained Earnings | (156.78M) | (110.67M) | (159.96M) | (211.75M) | (292.16M) |
| Accumulated OCI | (2.44M) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 239.04M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.18M | (77.53M) | (123.73M) | 63.14M | 47.7M |
| Total Debt | 209.17M | 12.4M | 11.69M | 8.65M | 1.97M |
| Net Debt | 118.05M | (70.8M) | (26.69M) | (55.39M) | (107.54M) |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.